Sanofi/Lunsekimig: Exploratory Velvet Phase 2B Study Did Not Meet Its Primary Endpoint

robot
Abstract generation in progress

Sanofi announced that its exploratory Velvet Phase 2B study for Lunsekimig did not achieve its primary endpoint. This brief update was reported by Reuters. Further details about the study’s implications were not provided.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin